Back to Careers

Hanadie Yousef, PhD

linkedin-icon-green

Dr. Hanadie Yousef is a leading expert on the biology of aging and mechanisms underlying tissue degeneration with over two decades of experience in biomedical research. In 2018, she launched Juvena Therapeutics, a venture-backed biotechnology company mapping the therapeutic potential of secreted proteins to develop biologics that prevent, reverse and cure chronic and age-related diseases. The company has secured about $60M to date and developed a proprietary pro-regenerative protein library supported by a computationally driven drug discovery and development platform that enables them to characterize human stem cell-secreted proteins for therapeutic potential. Their artificial intelligence-enhanced platform leverages multiple data modalities and technologies, including quantitative proteomics, multi-omics, high-content imaging and machine learning. Juvena’s scaling platform has enabled the identification, extensive preclinical validation, and lead optimization of three novel drug candidates, including a lead recombinant fusion protein headed towards an investigational new drug and anticipated to enter the clinic in 2024 for Myotonic Dystrophy Type 1, as well as mutliple discovery candidates with in vivo efficacy across several chronic, age-related and rare metabolic and muscle degenerative disease areas.

Dr. Yousef’s high-impact published research has been supported by fellowships and grants from the National Institute of Health (NIH), National Science Foundation, SPARK, and the California Institute for Regenerative Medicine and led to multiple issued and pending patents. She has received multiple awards and been named to various shortlists for her entrepreneurship and innovation, including the Biocom Catalyst award in 2022, Emerging Pharma Leader by Pharmaceutical Executive, Business Insider 30 under 40 in Healthcare, and Endpoints 20 under 40 lists in 2023. She earned her B.S., summa cum laude from Carnegie Mellon University and a PhD from UC Berkeley as an NSF graduate research fellow then completed a 5-year postdoctoral fellowship at Stanford School of Medicine as an NIH fellow and SPARK scholar.

Learn more about Hanadie

LinkedIn
PubMed Library
PostDoc Research
Graduate Research
Undergraduate Research and Achievements
ResearchGate

Back to Careers

Jeremy O’Connell, PhD

linkedin-icon-green

As Chief Scientific Officer and Co-Founder of Juvena Therapeutics, Dr. O’Connell oversees research strategy, pre-clinical science and manufacturing, and intellectual property efforts. Dr. O’Connell’s expertise in proteomics and systems biology expert accrued during a PhD from UT Austin, a postdoc at Harvard, and his time in industry.

Prior to Juvena Therapeutics, in his postdoctoral fellowship at Harvard Medical school in the lab of Steven Gygi, he leveraged large proteomics datasets to build machine learning classifiers to improve protein-protein interaction predictions within the ubiquitin system.

He has spearheaded research projects in multiple tier-one research institutions, including Harvard and Stanford, employing a combination of mass spectrometry, high throughput imaging, and computational approaches. His work has resulted in numerous peer-reviewed publications, approved and pending patents, millions in award grant funding as the primary PI, fellowships, and awards.

Learn more about Jeremy

PubMed Library
LinkedIn

Back to Careers

Fengling Liu, PhD

linkedin-icon-green

Dr. Fengling Liu brings over 10 years of industry experience developing multiple biologics. Since 2010 she served as the Protein Biochemistry lead or group lead of Protein Science in multiple biotechs in the bay area including Medimmune (AstraZeneca), Relypsa, Atreca and Arcus Biosciences.

Her protein science-focused research spanned target identification/confirmation, lead optimization, protein purification and engineering to support vaccine development, small molecule and antibody drug discovery in infectious disease and Immuno-Oncology. She was trained in Biochemistry and Structure Biology during her PhD at Georgia State University. She studied the molecular basis of HIV protease drug resistance through enzyme kinetics and X-ray crystal structures.  She solved over a dozen super high resolution crystal structures of HIV/drug complexes and discovered a novel drug resistance mechanism.

During her postdoc in the lab of Professor Ted Jardetzky in the Structural Biology Department at Stanford Medical School, Dr. Liu studied human viral glycoprotein interactions to discover viral entry inhibitors.

Besides her passion for science and technology, Fengling also enjoys gardening and hiking with family and friends.

Learn more about Fengling

LinkedIn

Back to Careers

Neil Berkley, MS, MBA

linkedin-icon-green

Neil Berkley brings over 20 years of experience in corporate development, business development, and strategic planning from large pharma, midsize biotech/pharma and small biotech companies. He has completed a wide variety of transactions including in- and out-licensing transactions, M&A transactions, co-development/co-investment/co-commercialization transactions, research collaborations, financing transactions, device and supply agreements, etc.   Neil has built and lead multiple business development, corporate development and alliance management teams.

Prior to joining Juvena, Neil was Chief Business Officer at AbCellera, a public biotech company focused on discovering novel antibody therapeutics. Previous to AbCellera, Neil was Vice President, Head of Business Development at Halozyme Therapeutics, a public biotechnology company focused on enabling platforms for the pharmaceutical industry. Neil has also held various business development and corporate development roles at Axerovision, COI (Avalon Incubator), Acadia, and GSK. Earlier in his career, Neil was Head of Business development at Cadence Pharmaceuticals, where he helped sell the company for $1.3B in cash. Neil also co-founded and helped build two San Diego-based biotechnology companies, Mpex Pharmaceuticals (acquired by Aptalis) and Vaxiion (a clinical stage bladder cancer company). 

Neil holds a BS in molecular biology from the UC San Diego, as well as a Master of Science in cellular and molecular biology and an MBA from San Diego State University.

Learn more about Neil
LinkedIn

Back to Careers

Zhihua Li, PhD

Dr. Li is a biologist with a multidisciplinary background in Biochemistry, Immunology, Cell and Molecular Biology, with 7 years of research experience in academia and 4 years in industry. He joined Juvena Therapeutics as a Protein Engineering Scientist to build protein expression and purification pipelines and to improve Juvena Therapeutics’ pipeline library of rejuvenating proteins for therapeutic purposes.

Following a BS in Biochemistry and Master’s Degree (MS) in genetics from scientific and technical universities in China, and a second MS in Molecular Microbiology and Immunology from the University of Southern California all during which he conducted research, Dr. Li completed his PhD (2007) and postdoctoral training (2014) in Cell and Molecular Biology from UT Austin, where he studied protein-protein interactions in different ways: first by combining computational predictions with experimental validations to discover 15 new protein factors functioning in the biogenesis of ribosomes; then by combining powerful mass spectrometry with protein fractionation techniques to create protein complex maps for both yeast and human cells. Continuing his exploration of novel protein interactions in his postdoctoral research, Dr. Li elucidated the self-cleavage mechanism of a novel membrane-bound transcription factor that drives oligodendrocyte differentiation. He’s published multiple co-authorships and first authorship studies along the way. 

Before joining Juvena, Dr. Li worked in industry and biotech startups as Lead Scientist, Life Science Consultant, Scientific Advisor and R&D director. As Lead Scientist at BMLogic, Dr. Li developed and optimized the protein secretory production system in Pichia, leading to improved protein secretion efficiency and greatly reduced protein degradation.

Besides his passion for science, he enjoys spending time with his kid and exploring nature.

Learn more about Zhihua

Google Scholar

Back to Careers

Thach Mai, PhD

linkedin-icon-green

Dr. Thach Mai joined Juvena Therapeutics as a Stem Cell Biologist and Bioinformatician to lead the validation and discovery of the key rejuvenating protein factors in Juvena Therapeutics’ complex embryonic secretome cocktail and develop and improve Juvena’s HTS platform for protein therapeutic discovery.

Dr. Mai is a trained stem cell biologist and immunologist with a focus on the mechanisms of muscle degeneration and aging. Dr. Mai received his PhD in Molecular Biology and Immunology from UC Irvine and a postdoctoral fellowship at Stanford University. During his fellowship, Dr. Mai used bioinformatics to accurately quantify high-throughput genomics data from multi-nucleated cells (heterokaryons) consisting of human and mouse gene transcripts to discover a novel transcription factor that drives the reprogramming of fibroblasts to pluripotency. Self-taught in ML with a strong passion for rapid biological discovery, he has generated deep learning models that identify muscle-specific aging genotypes as well as a machine learning classifier for the myogenic differentiation state of a single cell with a heterogeneous population.

Dr. Mai has been awarded multiple fellowships including from the National Institute of Health (F32), has three, 1st author publications including in Nature Journals, and is co-author of thirteen publications with one in review.

Learn more about Thach

PubMed Library
LinkedIn

Back to Careers

Mo (Mohammad) Tabrizi, PhD

linkedin-icon-green

Mo (Mohammad) Tabrizi, PhD brings over 25 years of experience in basic research, integrative pharmacology, translational sciences, and development of biologics. Prior to Joining  Juvena Therapeutics, Dr. Tabrizi served in positions with increasing responsibilities at large companies such as Merck Research Laboratories, Medimmune (acquired by AstraZeneca), Abgenix (acquired by Amgen), and biotech companies such as Soteria Biotherapeutics and Acendis pharma. His product development experience spans many therapeutic areas including oncology, immune-oncology, and inflammatory diseases.

He has been an author or co-inventor on more than 50 original papers, reviews articles, published books and patents. Dr. Tabrizi has been an invited speaker to numerous national and international conferences. Dr. Tabrizi received his bachelor’s degree in Pharmacy from University of Houston (Summa Cum Laude) and his PhD from University at Buffalo, State University of New York (SUNY) in Pharmaceutical Sciences. He completed a postdoctoral training in Pharmacology at University of New York at Buffalo (SUNY) with a focus on therapeutics.

 

Learn more about Mohammad

LinkedIn

Back to Careers

Sharon Louie, PhD

linkedin-icon-green

Sharon joined Juvena Therapeutics as a Senior Scientist working on preclinical in vivo disease modeling and drug discovery. She received her B.S. in Molecular Toxicology and Ph.D in Metabolic Biology from UC Berkeley where she used chemoproteomic and metabolomic technologies to uncover metabolic drivers of triple-negative breast cancers. Sharon completed her post-doctoral training at Boston Children’s Hospital/Harvard Medical School where she developed a transplantation assay for lung stem cell-derived organoids to mouse models with lung disorders to assess the potential for future cell therapies. She then spent a few years in the biotech industry leading studies to support preclinical drug development.

Sharon has been awarded multiple fellowships during her time in academia, including the NSF graduate fellowship and the Hope Funds for Cancer fellowship. She is a co-author on 22 publications.

 

Learn more about Sharon
LinkedIn

Back to Careers

Vengadeshprabhu Karuppa gounder, PhD

linkedin-icon-green

Dr. Vengadeshprabhu Karuppa gounder, PhD, joined Juvena Therapeutics as a Scientist II working on preclinical in vivo disease modeling and drug discovery. Dr. Karuppa gounder brings over 10 years of pharmacology & drug development experience in academic research. Dr. Karuppa gounder has strong background in pharmacology, immunology and molecular biology. He has several years of experience developing preclinical animal models in areas of diabetes, NASH, cardiomyopathy, autoimmune diseases, aging, osteoarthritis, IBD, renal and inflammatory diseases.

Dr. Karuppa gounder completed his Undergraduate and Master’s work on Pharmaceutical Sciences at the TamilNadu DR. MGR Medical University, Chennai, India and did his Ph.D. studies at Niigata University of Pharmacy and Applied Life Sciences, Japan, where he studied the role of HMGB1 and GPCR role in diabetes and autoimmune disease models. Then he joined as a postdoctoral researcher at Penn State College of Medicine, PA. During his fellowship, Dr. Karuppa gounder established new methods to study the role of GPCR signaling in synovitis, osteoarthritis and osteoporosis in mouse models and treatment options.

Dr. Karuppa gounder achieved the first author in leading scientific journals, Science Translational Medicine, & Aging Research Reviews and co-author of several research and review articles, and bagged several awards and grants.

 

Learn more about Vengadeshprabhu

LinkedIn

Back to Careers

Ritwik Datta, PHD

linkedin-icon-green

Ritwik Datta joined Juvena Therapeutics as a Scientist on the Pharmacology team. Ritwik is a physiologist with over ten years of experience. His expertise lies in comprehending the molecular basis of cardiometabolic diseases. Ritwik’s approach to investigating complex biological questions involves utilizing both mouse models and cell-based methods to develop innovative therapies for cardiometabolic and pulmonary diseases.

Ritwik received his Ph.D. from the University of Calcutta under the guidance of Sagartirtha Sarkar, Ph.D. Ritwik focused on studying how two major cell types in the heart – cardiac myocytes and fibroblasts – communicated with each other through secreted molecules and how these signaling pathways impacted cardiac fibrosis.

Ritwik completed his extensive postdoctoral training at the University of California, San Francisco (UCSF) in the lab of Kamran Atabai, MD. Ritwik’s research identified a novel integrin-mediated feedback loop of insulin receptor signaling that regulates skeletal muscle insulin sensitivity, laying the foundation for integrin-based therapy to lower daily insulin needs in diabetic patients. In his recent work, Ritwik investigated integrins’ role in regulating dietary fat metabolism in the intestine, providing insights into how intestinal lipid droplet homeostasis affects whole-body lipid metabolism and cardiovascular health.

Throughout his career, Ritwik has garnered recognition and support from prestigious organizations, including postdoctoral fellowships from the Larry L Hillblom Foundation, enabling him to pursue his research endeavors. Ritwik has 6, 1st author publications including in PNAS and Cell reports, and he is a co-author of 10 publications in leading scientific journals.

Besides his passion for science, Ritwik is a travel and photography enthusiast.

 

Learn more about Ritwik

PubMed Library
LinkedIn